GlaxoSmithKline to discontinue manufacture and supply of Zin
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
GlaxoSmithKline Pharmaceuticals on 21 May 2020, said that it has made a decision to discontinue the manufacture and supply of Zinetac tablets (150 mg and 300 mg products) manufactured in India.

And will in due course request cancellation of the marketing authorization associated with the drug, GlaxoSmithKline Pharmaceuticals said in a regulatory filing.

In the coming months, the drug firm will work closely with the regulatory authorities, it added. The drug firm was contacted by regulatory authorities regarding the detection of cancer-causing N-Nitrosodimethylamine (NDMA) in Zinetac (ranitidine) products.

Based on the information received and correspondence with regulatory authorities, the company made the decision in September 2019 to initiate a voluntary recall of all ranitidine products in all markets as a precautionary action.

Source: https://www.outlookindia.com/newsscroll/glaxosmithkline-to-discontinue-zinetac-tablets-in-india/1841758
J●y P●●●●r and 8 others like this9 shares
Like
Comment
Share
Dr. S●●●●●m S●●●●y P●●●●●l
Dr. S●●●●●m S●●●●y P●●●●●l General Medicine
It is a matter of great concern that such a wonder drug is in fact containing Cancer creating compounds. However,does GSK not have the technology to remove the Cancer causing substances instead of the complete ban?
May 23, 2020Like